Tirofiban simulant

PreclinicalSmall molecule

TThe First Hospital of Jilin University

Tirofiban simulant is one of 27 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Repatha

Amgen

Preclinical

2 2

Levaquin

WWim Janssens

Preclinical

3 3

Tylenol

KKenvue Brands

Preclinical

1 4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Statins

Sanofi

Preclinical

1 7

Urokinase

Mmedac GmbH

Preclinical

3 8

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 9

Actilyse

Boehringer Ingelheim

Preclinical

1 10

Magnesium

SSpherium Biomed

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Ischemic Stroke

NCT06045156

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Recruiting·TThe First Hospital of Jilin University·N/A·NCT06045156·1,084 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tirofiban simulant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tirofiban simulant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tirofiban simulant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Hospital of Jilin University

Tirofiban simulant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News